Search Results for "days"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for days. Results 1101 to 1110 of 1864 total matches.

Drugs for COPD

   
The Medical Letter on Drugs and Therapeutics • Sep 02, 2024  (Issue 1710)
generic 460.80 Spiriva Respimat 2.5 mcg/inh SMI (60 inh/unit) 2 inh once/day 527.40 Umeclidinium ...
The main goals of treatment of chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, prevent disease progression, and reduce mortality. GOLD (Global Initiative for Chronic Obstructive Lung Disease) guidelines for treatment of COPD were updated recently. Treatment of acute exacerbations is not discussed here. Drugs available for treatment of COPD are listed in Tables 1 and 3.
Med Lett Drugs Ther. 2024 Sep 2;66(1710):137-44   doi:10.58347/tml.2024.1710a |  Show IntroductionHide Introduction

Comparison Table: Some Drugs for Plaque Psoriasis (online only)

   
The Medical Letter on Drugs and Therapeutics • Sep 30, 2024  (Issue 1712)
, or suspension and 60 g every 4 days for foam) Ointment and foam can be applied for up to 4 weeks and cream ...
View the Comparison Table: Some Drugs for Plaque Psoriasis
Med Lett Drugs Ther. 2024 Sep 30;66(1712):e160-6   doi:10.58347/tml.2024.1712b |  Show IntroductionHide Introduction

Two New Drugs for Glaucoma

   
The Medical Letter on Drugs and Therapeutics • Jul 16, 2018  (Issue 1551)
% throughout the night and following day. They are generally well tolerated and have few, if any, systemic ...
The FDA has approved two new ophthalmic drugs for reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension: latanoprostene bunod (Vyzulta – Bausch and Lomb), a modified prostaglandin analog, and netarsudil (VRhopressa – Aerie), the first Rho kinase inhibitor to be approved in the US.
Med Lett Drugs Ther. 2018 Jul 16;60(1551):117-20 |  Show IntroductionHide Introduction

Drugs for Cough

   
The Medical Letter on Drugs and Therapeutics • Dec 17, 2018  (Issue 1562)
the next day. A single 50-mg dose of diphenhydramine caused more errors on a driving simulation test than ...
Acute cough (<3 weeks in duration) generally does not require pharmacologic treatment, especially in children. Suppression of productive cough may be harmful. Management of patients with cough should include elimination of any precipitating factor (e.g., cigarette smoking) and treatment of any underlying cause such as upper airway cough syndrome, gastroesophageal reflux disease, asthma, or other pulmonary disease.
Med Lett Drugs Ther. 2018 Dec 17;60(1562):206-8 |  Show IntroductionHide Introduction

Cefuroxime Axetil

   
The Medical Letter on Drugs and Therapeutics • Jun 03, 1988  (Issue 767)
Chemother, 19:109, 1987). One seven-day trial in England found cefuroxime axetil, 250 or 500 mg q12h, less ...
Cefuroxime axetil (Ceftin - Glaxo), an oral form of the second-generation parenteral cephalosporin cefuroxime (Zinacef), was recently marketed in the USA. Previously available oral cephalosporins are the first-generation drugs cephalexin (Keflex; and others), cephradine (Anspor; and others) and cefadroxil (Duricef; and others), and the second-generation cefaclor (Ceclor); second-generation cephalosporins have more activity against gram-negative bacteria.
Med Lett Drugs Ther. 1988 Jun 3;30(767):57-9 |  Show IntroductionHide Introduction

Troglitazone for Non-Insulin-Dependent Diabetes Mellitus

   
The Medical Letter on Drugs and Therapeutics • May 23, 1997  (Issue 1001)
to 600 mg once 160.20 * Cost to the pharmacist for 30 days’ treatment with lowest daily dosage based ...
Troglitazone (Rezulin - Parke-Davis), the first of a new class of thiazolidinedione derivatives ('glitazones') for diabetes, has been marketed for oral treatment of noninsulin- dependent diabetes mellitus (NIDDM) in patients who take more than 30 units of insulin daily and still have a glycosylated hemoglobin concentration (HbA1c) of 8.5% or higher.
Med Lett Drugs Ther. 1997 May 23;39(1001):49-51 |  Show IntroductionHide Introduction

Gleevec (STI-571) For Chronic Myeloid Leukemia

   
The Medical Letter on Drugs and Therapeutics • Jun 11, 2001  (Issue 1106)
in less than 0.5% of patients. DOSAGE AND COST — The recommended dosage of imatinib is 400 mg/day (taken ...
Imatinib mesylate (STI-571; Gleevec - Novartis), an oral tyrosine kinase inhibitor, has received accelerated approval from the FDA for treatment of all phases of chronic myeloid leukemia (CML) after interferon has failed.
Med Lett Drugs Ther. 2001 Jun 11;43(1106):49-50 |  Show IntroductionHide Introduction

Ertapenem (Invanz) - A New Parenteral Carbapenem

   
The Medical Letter on Drugs and Therapeutics • Mar 18, 2002  (Issue 1126)
) 3 grams/100 mg q4-6h 60.40-90.60 * Cost to the pharmacist for one day’s treatment based on AWP ...
Ertapenem (er ta pen' em; Invanz - Merck), a carbapenem antibacterial with a narrower spectrum of activity than imipenem (Primaxin) or meropenem (Merrem), has been approved by the FDA for once-daily IV treatment of complicated intra-abdominal, urinary tract and skin and skin structure infections, acute pelvic infections, and community-acquired pneumonia.
Med Lett Drugs Ther. 2002 Mar 18;44(1126):25-6 |  Show IntroductionHide Introduction

Alosetron (Lotronex) revisited

   
The Medical Letter on Drugs and Therapeutics • Aug 05, 2002  (Issue 1136)
reported fecal urgency on 50% or more of days during a 2-week baseline period. The published study of 801 ...
The FDA recently announced that it will permit reintroduction of alosetron hydrochloride (Lotronex - GlaxoSmithKline) for treatment of irritable bowel syndrome (IBS). The drug was previously withdrawn from the market because of severe gastrointestinal toxicity. The reintroduced drug will have a 50% lower starting dose, a narrower indication and some other marketing restrictions (www.fda.gov/cder/drug/infopage/lotronex/lotronex.htm).
Med Lett Drugs Ther. 2002 Aug 5;44(1136):67-8 |  Show IntroductionHide Introduction

Teriparatide (Forteo) for Osteoporosis

   
The Medical Letter on Drugs and Therapeutics • Feb 03, 2003  (Issue 1149)
SC or IM every other day 155.16 Miacalcin Nasal Spray (Novartis) 200 IU intranasal daily 63.74 2 1 ...
Teriparatide (ter i par' a tide; Forteo - Lilly), a recombinant segment of human parathyroid hormone, has been approved by the FDA for parenteral treatment of osteoporosis in post-menopausal women, and in men with idiopathic or hypogonadal osteoporosis, who are at high risk for fracture. Teriparatide is the first approved treatment for osteoporosis that stimulates bone formation. Other drugs approved for this indication inhibit bone resorption (Treatment Guidelines from the Medical Letter 2002;1:13).
Med Lett Drugs Ther. 2003 Feb 3;45(1149):9-10 |  Show IntroductionHide Introduction